Scrip’s Rough Guide On The State Of RNAi

Much of industry's current attention is focused on gene therapies – and rightfully so, considering the therapeutic promise of such one-time cures, and the spate of M&A activity for gene therapy biotechs and manufacturers, despite justifiable concerns over its scalability and affordability. But some of those challenges serve to highlight the opportunities possible with a different breakthrough field – drugs that target RNA, either through double-stranded RNA-mediated interference (RNAi) or antisense oligonucleotides (ASOs).

Arguably overshadowed by gene therapies and their curative hype, RNA therapeutics are gaining prominence, with a number of approvals in...